BioSpace News Archive

- Nurtec ODT now the first and only medication for both acute and preventive treatment - New and encore clinical data presentations highlight the efficacy and safety of Nurtec ODT as both acute treatment of migraine and preventive treatment of episodic migraine

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the companys drug candidate EB01 has met a key interim study parameter. The company has now passed the initial inflection point of its Phase2b study and will continue enrolling the final cohort of patients.

Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a worldwide exclusive licence agreement with TekCyte Pty Ltd (TekCyte) in respect of TekCyte’s wound dressing technology. Cynata has also secured an option to purchase the relevant technology outright.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Conference

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®. Both patients were given access to Hemopurifier® treatment through Emergency Use

Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Wayne Godfrey, M.D., as Chief Medical Officer, effective June 1, 2021.

Dermavant Sciences, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration

Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY® (fremanezumab-vfrm) for the treatment of migraine, which is being presented at the American Headache Society (AHS) annual meeting, taking place virtually on June 3-6.

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases, announced that its investigational new drug (IND) application for CT120, a fully human CD19/CD22 dual-targeting chimeric antigen receptor (CAR)-T cell therapy,